Board and Management
Chris Burrell, Managing Director
Corporate lawyer with extensive experience in M&A, capital markets and commercialisation.
Jitto Arulampalam, Non-Executive Director
Jitto is a Non-Executive Director of Zucero Therapeutics. He is also the Executive Chairman of two Australian publicly-listed companies, TBG Diagnostics (ASX: TDL) and Lanka Graphite (ASX: LGR). He is a Melbourne-based businessman with over 20 years of extensive experience in corporate restructuring, capital raising, listing and running of public companies on the ASX.
Having started his career in accounting, Jitto spent more than 8 years with Westpac Banking Corporation before joining boards of public companies. In 2004, Jitto was appointed CEO of Newsnet where he was responsible for guiding the company through a successful restructure and positioned the company as a leading innovator in the messaging/telco space. In May 2010, he co-founded ASX-listed potash mining and exploration company Fortis Mining (ASX: FMJ), which was awarded the “IPO of the Year 2011”.
Jitto was also previously the Chairman of ASX-listed companies Great Western Exploration (ASX: GTE) and Medicvision (ASX: MVH). Jitto is a member of many professional bodies, including the Australian Institute of Company Directors.
Keith Dredge (PhD), Chief Scientific Officer
Keith has more than 18 years’ experience in cancer & immunology research, drug discovery & development, both in academia and industry. Previously, he held senior management positions at the ASX-listed Progen Pharmaceuticals Limited - playing a key role in the discovery and early development of PG545 - and TetraQ, a contract research organisation at The University of Queensland (UQ). Keith also held academic positions at UQ and at St. George’s University of London, UK where he was the first to identify and publish on the immunomodulatory and anti-angiogenic properties of Celgene’s Revlimid® and Pomalyst®, now approved anti-cancer drugs.
Keith has authored over 40 internationally-recognised scientific publications including several on Zucero’s main asset PG545 in The Journal of Clinical Investigation, Molecular Cancer Therapeutics, European Journal of Cancer, Oncotarget, PLoS One, British Journal of Cancer and Investigational New Drugs. Keith obtained his PhD in Pharmacology from the National University of Ireland, Galway and is a member of the American Association of Cancer Research (AACR) and the American Society of Clinical Society (ASCO).
Darryn Bampton (MMSc, Dip Reg Affairs), Chief Development Officer
Darryn has over 20 years’ experience in the pharmaceutical industry and commercial drug development including QC analyst and Regulatory Affairs roles at the Merck Generic Group of Companies in Australia, New Zealand and the UK, and a Regulatory Affairs Team Leader role at Origin Pharmaceutical Services (later Constella Group) in the UK. He established a presence for Constella in Australia before taking up a role as Director of Regulatory Affairs and Clinical Development at Progen Pharmaceuticals Ltd. In this role, he managed the PG545 clinical program and provided regulatory input into the CMC program and overall development strategy.
Darryn has extensive experience in the provision of strategic regulatory affairs planning, managing oncology and orphan drug regulatory projects, with a focus on the EU and US markets. Darryn holds a Master’s Degree in Medical Science (Drug Development) and a post graduate Diploma in Regulatory Affairs.